

HERSTON INFECTIOUS DISEASES INSTITUTE

DART 3: A pragmatic stepped wedge cluster randomised trial of ultrasound guidance to reducing multiple PIVC insertions in hospitalised patients

Dr Jessica Schults

on behalf of the larger investigator team:

Dr Nicole Marsh, Dr Amanda Ullman, Tricia Kleidon, Dr Robert Ware, Dr Joshua Byrnes, Emily Young, Dr Lisa Hall, Dr Gerben Keijzers, Dr Louise Cullen, Dr Pauline Calleja, Dr Steven McTaggart, Dr Nathan Peters, Dr Stuart Watkins, Dr Amanda Corley, Christine Brow, Zhen Lin, Frances Williamson, Luke Burgess, Dr Fiona Macfarlane, Dr Marie Cooke, Callan Battley

Acknowledgment of **Country**

We acknowledge the Traditional Owners and their custodianship of the lands on which we meet.

We pay our respects to their Ancestors and their descendants, who continue cultural and spiritual connections to Country.

We recognise their valuable contributions to Australian and global society.





No conflicts of interest to declare

“ PIVC insertion is one of the most practiced clinical procedures in hospitals, yet carries the greatest risk of failure of any medical device ”

Dr Evan Alexandrou



Difficult IntraVenous Access (DIVA)

Characterised by: Limited suitable veins

Evident in: Half of hospitalised patients; one-third of ED presentations

Defined by: So many ways...

Table 3. Multivariate regression analyses.

Factor	β	SE	<i>p</i> Value	Odds Ratio	95% CI
History of a difficult intravenous cannulation	0.976	0.180	<0.001	2.7	1.6 to 4.4
Practitioner's expectation of a difficult intravenous access	0.936	0.191	<0.001	2.6	1.6 to 4.0
No palpable vein after tourniquet placement	1.670	0.187	<0.001	4.8	2.5 to 8.1
No visible vein after tourniquet placement	1.879	0.192	<0.001	5.9	2.5 to 10.1
Diameter of the vein less than 3 millimeters after tourniquet placement	1.247	0.094	<0.001	3.5	2.7 to 4.4

Constant β 8.950, SE 0.543, $p < 0.001$. SE = Standard Error. CI = Confidence Interval.

Carr et al JHM 2017

Scoping RV of 13 DIVA tools, rules and algorithms

Vein characteristics most common:

- Number/Quality/Size/Location/Visibility/Palpability

Risks:

- Chronic disease (Diabetes OR 2.1, SCD OR 3.5, IVU OR 2.4)
- Obesity or emaciated
- Smaller gauge OR 6.4
- History of DIVA

Success:

- Visible veins OR 0.79-5.05
- ↑ procedural volume OR 4.4
- Certification
- Predicted success OR 1.06




Consumer experience of DIVA

- 1st time success 44-58% inpatients, 77%-86% ED
 - 25% had multiple inserters
 - Some patients 10 attempts
 - 28% had procedure abandoned or a CVAD inserted
- Kleidon et al, JPCH 2019*
Farrell et al, Canc Nurs Prac 2017
Marsh et al, JHM 2018
Rippey EMA 2016
Marsh et al, Trials 2018

Consumer survey (Cooke PLoS One 2018)

Questions	Adult Survey	n (%)	Paediatric Survey	n (%)	p value
	Responses		Responses		
	n = 570		n = 142		
Last time you/your child needed an IV, how painful or stressful was the experience? *	Median (IQR)	4 (2, 7)		7 (5, 9)	<0.001^
1 = no pain/distress;	Minimal pain/distress (≤ 3)	268 (47.5)		25 (18)	
10 = extreme pain/distress	Moderate (4–7)	197 (34.9)		45 (32.4)	
	Severe pain/distress (≥ 8)	99 (17.5)		69 (49.6)	



1.
Assess
intravenous
access needs

2.
Inform
and partner
with patients

3.
Ensure
competency

4.
Choose the
right insertion
site and PIVC

5.
**Maximise
first insertion
success**

6.
Insert
and secure

7.
Document
decisions
and care

8.
Routine use:
inspect, access
and flush


9.
Review
ongoing
need

10.
Remove safely
and replace
if needed




SCAN ME

Ultrasound: Maximising first attempt success



(Van Loon et al. Brit J Anaesth 2018)

Workforce issues



DART3 - DIFFICULT ACCESS REQUIRES THOUGHT, TRAINING AND TECHNOLOGY

Co-developing an ultrasound pathway for patients with difficult intravenous access

Phase n° 1

Stakeholder and
consumer interviews

Literature reviews of
DIVA tools


Phase n° 2

Co-development and pilot test
DIVA tools + implementation
strategies

Evaluation of funding for PIVC
insertion

Phase n° 3

Implement and evaluate the DIVA
identification and escalation pathway
effect on clinical and implementation
outcomes





STUDY PROTOCOL

Open Access



Improving difficult peripheral intravenous access requires thought, training and technology (DART³): a stepped-wedge, cluster randomised controlled trial protocol


Jessica A Schults^{1,2,3,4,5,6*}, Nicole Marsh^{1,4,5}, Amanda J Ullman^{1,4,5,6,7}, Tricia M Kleidon^{1,4,5,6}, Robert S Ware⁸, Joshua Byrnes^{8,9}, Emily Young⁸, Lisa Hall^{3,10}, Gerben Keijzers^{8,11,12}, Louise Cullen¹³, Pauline Calleja^{5,14}, Steven McTaggart^{6,7}, Nathan Peters^{15,16}, Stuart Watkins¹¹, Amanda Corley^{1,4,5}, Christine Brown¹, Zhen Lin¹, Frances Williamson^{13,15,17}, Luke Burgess⁴, Fiona Macfarlane⁶, Marie Cooke⁵, Callan Battley^{6,7} and Claire M I

Abstract

Background Peripheral intravenous catheters (PIVCs) are the most used invasive medical device in health around half of insertion attempts are unsuccessful leading to delayed medical treatments and patient discomfort. Ultrasound-guided PIVC (USGPVC) insertion is an evidence-based intervention shown to improve success especially in patients with Difficult IntraVenous Access (BMC Health Serv Res 22:220, 2022), however the implementation in some healthcare settings remains suboptimal. This study aims to co-design interventions that optimise ultrasound guided PIVC insertion in patients with DIVA, implement and evaluate these initiatives and develop scale up activities.

Methods A stepped-wedge cluster randomized controlled trial will be conducted in three hospitals (two adult, one paediatric) in Queensland, Australia. The intervention will be rolled out across 12 distinct clusters (four per hospital). Intervention development will be guided by Michie's Behavior Change Wheel with the aim to increase local staff capability, opportunity, and motivation for appropriate, sustainable adoption of USGPVC insertion. Eligible clusters include all wards or departments where > 10 PIVCs/week are typically inserted. All clusters will commence in the control (baseline) phase, then, one cluster per hospital will step up every two months, as feasible, to the implementation phase, where the intervention will be rolled out. Implementation strategies are tailored for each hospital by local investigators and advisory groups, through context assessments, staff surveys, and stakeholder interviews and informed by extensive consumer interviews and consultation. Outcome measures align with the RE-AIM framework including clinical-effectiveness outcomes (e.g., first-time PIVC insertion success for DIVA patients [primary outcome], number of insertion attempts); implementation outcomes (e.g., intervention fidelity, readiness assessment) and cost effectiveness outcomes. The Consolidated Framework for Implementation Research framework








Public, university affiliated paediatric hospital

Public, university affiliated adult hospitals x 2

Hospital and location	Setting	Inpatient Beds	Cluster wards
Gold Coast University Hospital; Gold Coast, QLD	Metropolitan	750	<ul style="list-style-type: none">• Emergency/Medical Decision Unit• Cancer and Blood Disorders• Vascular• Trauma and Orthopaedics
Queensland Children's Hospital; Brisbane, QLD	Metropolitan	359	<ul style="list-style-type: none">• Paediatric Intensive Care• Inpatient Surgical• Inpatient Medical• Infants including neonates
Royal Brisbane and Women's Hospital; Brisbane, QLD	Metropolitan	929	<ul style="list-style-type: none">• General Surgical• General Surgical and Colorectal• Coronary Care Unit• Emergency and Trauma Centre



Participants

Eligible clusters:

Emergency departments, inpatient wards, or day procedure units where >10 PIVCs/week are typically inserted.

* We excluded operating theatres, radiology, rehabilitation, or psychiatric units. Clinician emergencies where IO access was used were also excluded.

Included PIVC: Any patient (DIVA or non-DIVA) of any age requiring a PIVC

Sample size: Target 1680 observations

20 PIVC insertions per ward, per two-month step was expected, plus a further 20 PIVC insertion during each of the sustainability phases

Outcomes

Table 1 DART³ outcomes. Outcomes, definitions, and data collection organised by RE-AIM domains

Outcomes	Information	Data source
<i>Patient and service level outcomes</i>		
Primary		
First attempt insertion success in patients identified as DIVA	One needle puncture, by one inserter, to achieve successful insertion of a functional (can be aspirated/flushed) PIVC ²	Hospital-based assessments
Secondary		
First attempt insertion success for all patients (regardless of DIVA status)	One needle puncture, by one inserter, to achieve successful of a functional (can be aspirated/flushed) PIVC ²	Hospital-based assessments
Number of attempts	Number of skin punctures to attempt PIVC insertion ³	Hospital-based assessments
Procedure outcome:	Successful PIVC insertion; time from PIVC referral to PIVC insertion (censored at 48 h); alternate device; alternate route (e.g., oral) ⁴	Hospital-based assessments
PIVC failure	Composite measure of local infection, primary bloodstream infection (BSI), occlusion, infiltration/extravasation, dislodgement (includes leaking), thrombosis and/or phlebitis ^{6,7}	Hospital-based assessments
Insertion/post-insertion complications	Bruising, haematoma, nerve injury, arterial puncture, or skin injury as well as the individual components of PIVC failure (above) ^{6,8}	Hospital-based assessments
PIVC dwell time	Time from PIVC insertion to PIVC removal (in hours) ⁶	Hospital-based assessments
PIVC necessity	PIVC used for fluids or medications within 24 h (excluding patients who require a prophylactic PIVC in situ as part of their treatment e.g., status epilepticus) ⁵	Hospital-based assessments
Incidence of blood stream infection	Cluster level routinely-collected rates of primary BSI and <i>S. Aureus</i> BSI ⁹	Hospital-based assessments
Economic outcomes		
Cost-effectiveness	Direct and indirect healthcare costs to the health system, patients/ carers: (time to insertion/therapy, cost of products, number of staff, staff time, costs of responding to failed insertion including cancelled appointments)	Hospital-based assessments

DART³ Intervention

co-designed

1. Vein assessment tool

2. Escalation pathway +/- USG

3. Implementation strategies, including

- Education on the use of the DIVA tool and escalation pathway

- Training in ultrasound guided PIVC insertion

- Support for trained staff (nurses and doctors) to become competent ultrasound guided PIVC inserters.

DIVA classification

Classified as **non-DIVA**, **potential DIVA** or **DIVA** by site DIVA assessment tool

- *N.B. In baseline, vein assessment was by the inserter.*

Updated January 2021
Feedback welcome:
j.schults@griffith.edu.au

Always Consider Whether Intravenous Therapy is Necessary?

The DIVA Key

Difficult IntraVenous Access

	Low Risk	Medium Risk	High Risk
1. <u>A</u> cuity	No clinical urgency (>2h)	Time critical (<2h)	Urgent
2. <u>A</u> pppearance	Multiple visible/palpable veins	Few visible/palpable veins	Nil visible/palpable veins
3. <u>A</u> lerts	Previous easy access	Multiple attempts required in past	Documented alert and/or US guidance required in past
4. <u>A</u> dmissions	Previously well or mild illness	Multiple admissions and/or comorbidities	Severe comorbidities and prolonged hospital care
5. <u>A</u> ge	> 3 years	< 3 years	< 18 months History of prematurity
6. <u>A</u> nxiety	Minimal anxiety	Moderate anxiety	Severe anxiety and/or documented needle phobia

Clinician Self Assessment

	Developing	Confident	Advanced
7. <u>A</u> bility	<100 paediatric insertions <50% first pass success Minimal US skills	100-800 paediatric insertions 50-80% first pass success Developing US skills	>800 paediatric insertions >80% first pass success Proficient US skills

Insertion & Escalation Pathway

Does your insertion ability = patient DIVA risk?

	Developing Inserter	Confident Inserter	Advanced Inserter
8. <u>A</u> scend	From Treating Team 2 Attempts Max	+/- Ultrasound Guided 2 Attempts Per Inserter	Preferably US Guided

Maximum 2 attempts per inserter from any ability level
After 4 insertion attempts **ESCALATE** to an **Advanced Inserter**

VAMS (7am-3pm)
Anaesthetist x4511
PICU Reg x4441 / x4442

Always Provide Procedural Support

Consider where appropriate


- 1) Numbing cream
- 2) Sucrose or breast feed
- 3) Comfort position
- 4) Distraction

Consider for Anxious Patients

Inhaled Entonox* or Quantiflex*
Enteral sedation
Refer to procedure CHQ-PROC-00303,
CHQ-PROC-62111



Implementation strategies



Get pills



Take pills



Feel better

CFIR components

Intervention characteristics

- Co-designed intervention
- Flexible escalation
- Multidisciplinary and collaborative approach

Inner setting

- Cultural belief ultrasound is for medical staff
- Staff shortages influencing escalation processes and choice of intervention
- Staff shortages influenced training availability

Outer setting

- Staffing shortages
- Changes to cluster composition
- COVID-19 impacts

Characteristics of individuals

- Clinical staff fatigued
- Heavy workloads
- Staff supportive of change
- Staff believe in the effectiveness of identifying DIVA early

Process

- Co-designed implementation toolkit



Implementation Research Logic Model: How DART3 is envisaged to work

Implementation strategies

- Customised DIVA tool and escalation pathway established at each site and adapted for Emergency and ICU departments (for in-house escalation)
- Lanyards with escalation pathway for ward nursing staff.
- Badges and magnets to identify Ultrasound competent PIVC inserters
- Ultrasound machines sourced for each participating ward.
- Training, USGPVC workshops, hospital wide and ward specific as well as bedside education and support by research nurses.
- Mentoring / shadowing for USGPVC trained nurses with vascular experts / teams
- Identification and upskilling of change champions for each participating ward
- Regular (per step) feedback for each site and ward with recruitment numbers, first attempt insertion success and upcoming news, such as workshops.
- Development and local endorsement of clinical skill assessment tool for ultrasound guided PIVC insertion competency achievement in nursing staff.
- Coffee vouchers and doughnuts rewards for wards with biggest recruitment

Mechanisms

- Promotes multidisciplinary involvement
- Intervention flexible with cluster needs



Reduce:

- Number of attempts
- PIVC failure
- Insertion/post-insertion complications
- BSI infection


Cost outcomes

- Cost of PIVC insertion
- Incremental cost per incremental gain in first time insertion success


Implementation outcomes

- Implementation
- Reach
- Adoption
- Maintenance & sustainability







1. Glasgow RE, Vogt TM, Boles SM. **Evaluating the public health impact of health promotion interventions: the RE-AIM framework.** Am J Public Health. 1999;89(9):1322-7.
2. Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, et al. **RE-AIM Planning and Evaluation Framework: Adapting to New Science and Practice With a 20-Year Review.** Front Public Health. 2019;7:64.
3. Keith RE, Crosson JC, O'Malley AS, Crompton D, Taylor EF. **Using the Consolidated Framework for Implementation Research (CFIR) to produce actionable findings: a rapid-cycle evaluation approach to improving implementation.** Implement Sci. 2017;12(1):15.



1. Glasgow RE, Vogt TM, Boles SM. **Evaluating the public health impact of health promotion interventions: the RE-AIM framework.** Am J Public Health. 1999;89(9):1322-7.
2. Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, et al. **RE-AIM Planning and Evaluation Framework: Adapting to New Science and Practice With a 20-Year Review.** Front Public Health. 2019;7:64.
3. Keith RE, Crosson JC, O'Malley AS, Crompton D, Taylor EF. **Using the Consolidated Framework for Implementation Research (CFIR) to produce actionable findings: a rapid-cycle evaluation approach to improving implementation.** Implement Sci. 2017;12(1):15.

Results

Recruitment



Participant Demographics



Characteristics	Baseline Frequency (%) or Median (IQR) N=673	Implementation Frequency (%) or Median (IQR) N=685	3-mo sustainability Frequency (%) or Median (IQR) N=237	6-mo sustainability Frequency (%) or Median (IQR) N=235
DIVA tool outcome				
Potential DIVA	285 (43%)	300 (44%)	120 (51%)	89 (38%)
Definite DIVA	192 (28%)	162 (24%)	51 (21%)	76 (32%)
Non-DIVA	196 (29%)	223 (32%)	66 (28%)	70 (30%)
Sex				
Male	386 (53%)	388 (57%)	141 (56%)	145 (59%)
Age in years				
Children (<18 yrs)	2 (0.2 to 8)	2 (0.3 to 11)	1 (0.3 to 7)	3 (0.2 to 10)
Adults (>18 yrs)	64 (47 to 76)	65 (51 to 75)	64.6 (48 to 75)	67.2 (51 to 76)

Primary outcome: First attempt insertion success

DIVA pts


	Baseline	Implementation	Sustainability
First attempt success among DEFINITE DIVA patients	80/192 (42%)	89/162 (55%)	67/127 (53%)
First attempt success among POTENTIAL DIVA patients	161/284 (57%)	182/300 (61%)	131/209 (63%)
First attempt success among ALL DIVA patients	241/476 (51%)	271/462 (59%)	198/336 (59%) ➡ 1.5 (1.1 to 2.2)¹

All pts


First attempt success among all patients	434/707 (61%)	452/692 (65%)	318/487 (65%)
--	---------------	---------------	---------------

Predictability of study phase on study outcomes (adjusted for trial step)
Effect estimate (95% CI), ¹Odds ratio

Proportion of first attempt insertion success



All DIVA




All patients

Ultrasound adoption

	Baseline	Implementation	Sustainability
<u>First</u> attempt among DEFINITE DIVA patients	69/158 (44%)	80/138 (58%)	53/82 (65%) → 3.4 (1.9 to 6.8)
<u>First</u> attempt among POTENTIAL DIVA patients	71/227 (31%)	62/259 (24%)	35/151 (23%)
<u>First</u> attempt among ALL DIVA patients	140/385 (36%)	142/397 (36%)	88/233 (38%) 1.6 (1.1 to 2.5)
<u>Any</u> attempt among DEFINITE DIVA patients	129/190 (68%)	125/161 (77%)	95/125 (76%) → 1.9 (1.1 to 3.6)
<u>Any</u> attempt among POTENTIAL DIVA patients	127/280 (45%)	109/295 (37%)	65/206 (32%)
<u>Any</u> attempt among ALL DIVA patients	256/470 (55%)	234/456 (51%)	160/331 (48%)




Implementation outcomes



Ultrasound adoption first attempt RED DIVA patients



Reach: Ultrasound accreditation



*Example of conversion to ultrasound guided PIVC insertion competence at one site; Sign off and competency numbers are cumulative

Patient/carer/inserter satisfaction and pain with insertion procedure




	Baseline	Implementation	Sustainability
Patient/carer satisfaction with insertion procedure	9.0 (7.0 to 10.0)	9.0 (8.0 to 10.0)	10.0 (8.0 to 10.0)
Patient/carer pain with insertion procedure	3.0 (1.0 to 5.0)	3.0 (1.0 to 5.0)	2.0 (1.0 to 4.0)
Staff satisfaction with insertion procedure	8.0 (6.0 to 10.0)	9.0 (8.0 to 10.0)	9.0 (8.0 to 10.0)

Scale 0 -10 numerical rating
Predictability of study phase on study outcomes (adjusted for trial step)
Effect estimate (95% CI), ²correlation coefficient

Global health-service change is hard

Start with a golden circle and the question: "Why?"



TED Ideas worth spreading



Simon Sinek
Leadership expert



Ultrasound accreditation

Journal of Diagnostic Medical Sonography
Volume 35, Issue 5, September/October 2019, Pages 401-411
© The Author(s) 2019, Article Reuse Guidelines
<https://doi.org/10.1177/8756479319838234>



Literature Reviews

Accreditation, Diagnostic Med

Kimberly Sorrentino,

Abstract

There are few regulatory medical sonography (D based by the operator. accreditation, credential papers and 42 editorials sonography specialty

correlations between accreditation and improved quality and also a positive correlation between credentialing and improved image quality. The survey studies revealed overwhelming support for accreditation and credentialing. Many articles raised concerns about the unknown quality of sonograms performed in nonaccredited facilities or by uncredentialed sonographers. If facility accreditation and/or individual credentialing could be implemented nationwide in DMS, it may lead to increased quality within the field.

Journal of the Intensive Care Society

[J Intensive Care Soc.](#) 2018 Feb; 19(1): 15–18.

Published online 2017 Sep 28. doi: [10.1177/1751143717733163](https://doi.org/10.1177/1751143717733163)

PMCID: PMC5810880

PMID: [29456596](https://pubmed.ncbi.nlm.nih.gov/29456596/)

Bridging the logistical gap between ultrasound enthusiasm and accreditation

[George Reid](#),¹ [Jonathan Bedford](#),² and [Ben Attwood](#)¹

► [Author information](#) ► [Copyright and License information](#) [PMC Disclaimer](#)

The benefit of a vascular access specialist placing a peripheral intravenous catheter: a narrative review of the literature

*Nicole Marsh^{1,2,3,4}, Emil
¹Nursing & Midwifery Res

Table 1. Characteristics of included studies

Author (year)	State/Country	Setting	VAS team (label)	Comparison	Outcome measure
Bosma (2002)	British Columbia, Canada	Single centre; non-critical medical and surgical wards	'Infusion nurses'	<i>Not applicable</i>	Number of consultations; successful PIVC insertion
Carr (2010)	Galway, Ireland	Single centre; hospital wide	IV 'Cannulation Team'	Pre-post commencement of IV Cannulation Team	First-time insertion success
Da Silva (2010)	Sau Paulo, Brazil	Single centre; medical, surgery, haematology and oncology units	'IV Team'	Pre-post commencement of IV Team	First-time insertion success; number of PIVCs; phlebitis
Hunter (2003)	Wisconsin, USA	Single centre (Phase 2); medical and surgical wards	'Vascular Access Team'	<i>Unclear</i>	PIVC-related complication; number of insertion attempts
Palefski (2001)	Unknown, USA	Multi-centre; hospital wide, 'infusion centre'; and patients' homes	'Infusion nurse'	Generalist nurse	PIVC-related complications
Meier (1998)	Iowa, USA	Single centre; acute and critical care wards	'Specialised IV Team'	House staff, medical students, and ward nurses	Primary BSIs
Miller (1996)	Pennsylvania USA	Single centre; medical and surgical wards	'IV Therapy Team'	House staff and nursing personnel	PIVC-related infections
Scalley (1992)	Colorado, USA	Single centre; hospital wide	'IV Team'	'Non-IVT'	Phlebitis
Soifer (1998)	Illinois, USA	Single centre; medical inpatient service	'IV team'	Medical house staff	PIVC-related complications
Tomford (1984)	Ohio, USA	Single centre; general medical firms (inpatient and outpatient units)	'IV team'	Medical house staff	PIVC-related complications

Thank you

- Patients involved in the study
- DART3 project team
- DART3 investigators
- Hospitals and health service partners
- Policy and government partners
- National Health and Medical Research Council
- University affiliates



Let's talk

Get In *Touch*

Email Address

j.schults@uq.edu.au

“The secret to being good at anything is to approach it like a curious idiot, rather than a know-it-all genius.”
~ Mike Monteiro